Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26‐week, open‐label, prospective trial (Study ENA713B US32)

Abstract

Results from this study suggest the combination of rivastigmine capsule and memantine in patients with moderate AD is safe and tolerable. A greater reduction in the GI tolerability of rivastigmine has been established with rivastigmine transdermal patch.